Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

19. November 2024 08:00 ET | Quelle: Novartis Pharma AG

Novartis ranks first in 2024 Access to Medicine Index

The Index spotlights Novartis leadership in research and development, and governance of access, with Novartis ranking first in these sub-topics Novartis malaria access plans, widespread registration...
16. Juni 2022 01:15 ET | Quelle: Novartis Pharma AG

New research reveals the critical actions needed to ensure COVID-19-driven surge in virtual health and care drives health access and equity

COVID-19 pandemic triggered a massive surge in virtual health and care delivery across the world, with many countries embracing hybrid virtual and in-person services Report from the Broadband...
20. Juli 2021 07:05 ET | Quelle: Novartis Pharma AG

Novartis pledges 10-year commitment with Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and other leading organizations to co-create effective, measurable solutions for health equity

Novartis and the Novartis US Foundation to join forces with Thurgood Marshall College Fund, Morehouse School of Medicine, 26 other Historically Black Colleges, Universities and Medical Schools and...
28. Oktober 2020 02:15 ET | Quelle: Novartis International AG

Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19

Novartis has been granted an option to in-license global rights of MP0420 and MP0423 - multi-targeted direct acting antiviral therapeutic candidates demonstrating potential efficacy against...
02. April 2020 17:05 ET | Quelle: Novartis International AG

Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program

New clinical trial to evaluate Jakavi® (ruxolitinib) in patients with COVID-19 associated cytokine storm Cytokine storm is a type of severe immune overreaction that can result from coronavirus...